PDGFB

Researchers hypothesized that AMD and COVID-19 share common genetic risk factors and carried out a study that identified a novel association of the two diseases with variants in the PDGFB gene. This gene encodes a platelet derived growth factor (Pdgf) which has a role in the formation of new blood vessels and is involved in the abnormal blood vessel changes that occur in AMD. They also found that more severe COVID-19 outcomes were associated with AMD likely arising from genetic predisposition to dysfunction involving complement proteins, as well as with a higher level of Pdgf in blood serum. Recent evidence has emerged to suggest that age-related macular degeneration (AMD) is a clinical risk factor for increased risk for infection and mortality. AMD has been reported to confer higher risk of severe complications of SARS-CoV-2 infection, including respiratory failure and death (25 percent), a risk which is higher than Type 2 diabetes (21 percent) and obesity (13 percent). Considering these observations, researchers from Boston University Chobanian & Avedisian School of Medicine hypothesized that AMD and COVID-19 share common genetic risk factors and designed and executed a study that identified a novel association of the two diseases with variants in the PDGFB gene. This gene encodes a platelet derived growth factor (PDGF) which has a role in the formation of new blood vessels and is involved in the abnormal blood vessel changes that occur in AMD. They also found that more severe COVID-19 outcomes were associated with AMD likely arising from genetic predisposition to dysfunction involving complement proteins, as well as with a higher level of PDGF in blood serum. "Our findings add to the body of evidence for the increased risk of infection and mortality from COVID-19 among AMD patients. Our analysis lends credence to previously reported clinical studies that found those with AMD have a higher risk for COVID-19 infection and severe disease, and that this increased risk may have a genetic basis," explained co-corresponding author Lindsay A. Farrer, PhD, chief of biomedical genetics. The BU research team conducted a genome-wide search for variants that are jointly associated with AMD and each of three COVID-19 outcomes (infection rate, critical illness and hospitalization) using large genetic datasets that contained tens of thousands of individuals. These datasets were previously assembled and studied separately for genetic factors contributing to the risk of AMD and for each of the COVID-19 disease outcomes. Subsequently, the researchers analyzed publicly available data from patients with AMD or COVID-19 and control groups to assess the association of variants in PDGFB with the gene activity. Finally, they employed an analytical technique that allowed them to investigate causal relationships between PDGFB gene variants, PDGFB concentration in blood, AMD, and COVID-19 outcomes. According to the researchers, these findings suggest that lowering PDGFB gene activity and serum PDGF concentration may reduce the severity of COVID-19, particularly among older people. "Therapeutic strategies combining anti-VEGF therapy (a current treatment for AMD that limits blood vessel growth in the eye that can harm vision) with antagonists (drugs that bind to receptors) for blocking PDGF signaling have been considered even more effective than the single VEGF treatment and are currently under investigation in clinical trials," added co-corresponding author Manju L. Subramanian, MD, associate professor of ophthalmology. The researchers believe this discovery of shared genetic risk factors will require a larger sample size for critical illness and hospitalizations to better understand the shared pathology and risk factors that contribute to worsening clinical outcomes in both disease states. These findings appear online in the Journal of Clinical Medicine. This work was supported by National Institutes of Health grants RF1 AG057519, R01 AG069453, R01 AG048927, U19 AG068753, and U01 AG062602.

CARLSBAD, Calif., May 18, 2021 /PRNewswire/ -- Biologica Technologies, developers and marketers of ProteiOS® growth factor and OsseoGEN® cellular bone matrix, announced today the early topline results from a retrospective, multicenter study evaluating the safety and effectiveness of ProteiOS in foot and ankle arthrodesis (fusion) procedures. Thus far, study results have observed fusion rates that are higher than or comparable to fusion rates in other published studies of any other bone graft material, including but not limited to; autograft, cellular bone matrices, and PDGF-BB. In this retrospective, multicenter study, ProteiOS has thus far been evaluated in 79 patients undergoing 121 foot and ankle fusion procedures with the primary endpoint deemed successful fusion based on high resolution CT scans and radiographs assessed by a blinded, independent radiologist. Based on radiographic evaluation the data demonstrated a fusion rate of 75.2% at six months and 97.1% fusion at 12 months. Biologica Technologies plans to submit the full data for publication in a peer-reviewed journal in the coming months as additional patients results are analyzed. "These study results mirror the anecdotal evidence we have been hearing about ProteiOS from surgeons and sales representatives in the field," stated Jason Mattiello, Vice President of Sales. "It is exciting to have this data and also to be at our first in-person conference in over a year!" ProteiOS has been shown to include more than 600 naturally occurring growth factors including but not limited to BMP-2, PDGF, TGF-β1, and VEGF. The product is provided in a lyophilized-format that supports the use of virtually any scaffold during implantation, providing flexibility for the surgeon and hospital. About Biologica Technologies Founded in 2015, Biologica Technologies is a company focused on providing clinically relevant biologic solutions across multiple medical specialties. Biologica's core proprietary technology is the ability to access intracellular growth factors (GFs) found within allograft tissue. ProteiOS® growth factor and OsseoGEN® cellular bone matrix are the first products utilizing this technology and possess the highest amount of GFs within their respective biologic categories. The company is privately-held and headquartered in Carlsbad, CA Related Links